Compositions which include glucagon-like peptide-2 (GLP-2) analogs, GLP-2 analogs with reversible or non-reversible linkers attached to one or more amino acid positions of the GLP-2 analog, and GLP-2 analogs linked to one or more polyethylene glycol polymers (PEG) via reversible or non-reversible linkers are disclosed. Also disclosed are pharmaceutical compositions comprising: the GLP-2 analogs； GLP-2 analogs linked solely to reversible or non-reversible linkers； the reverse PEGylated GLP-2 analogs； and the non-reversibly PEGylated GLP-2 analogs, as well as methods of using the same.
